The US Supreme Court restored patients’ ability to order mifepristone by mail, reversing a federal appeals court stay on Monday. The decision came after mifepristone manufacturers sought immediate relief following the earlier ruling that had restricted the mail-order pathway. For biotech and healthcare stakeholders, the move reinforces that FDA-regulated distribution channels can remain fluid through the courts. It also signals that litigation posture and timing can quickly reshape access pathways even after FDA action. Companies with distribution, compliance, and patient-support operations tied to specialty drug dispensing should expect operational knock-on effects from changes in how quickly prescriptions can be routed through mail. Details of how plans will adjust to the restored pathway were not fully outlined in the report, but the decision is a direct procedural change affecting the deployment of mifepristone access nationwide.